ALLK - Allakos Analyst Turns Bullish Sees 'Significant Upside' If Study Results Are Positive | Benzinga
Shares of Allakos Inc (NASDAQ: ALLK) were climbing in early trading on Monday.
Despite past setbacks, lirentelimab has a "strong chance” of showing efficacy in the atopic dermatitis and chronic spontaneous urticaria readouts, according to William Blair.
The Allakos Analyst: Tim Lugo upgraded the rating for Allakos to Outperform.
The Allakos Thesis: The top-line results from two studies of subcutaneous lirentelimab is expected by either ...